Company News & Events

ORYZON Initiates Clinical Development of ORY-1001, a Novel LSD1 Inhibitor, in Patients with Acute Myeloid Leukemia

7 January 2014

The First Specific LSD1 Inhibitor to Enter the Clinic.

ORYZON, a biopharmaceutical company with a strong focus on epigenetics, has announced that has received the approval from the AEMPS on December 26th, 2013 to initiate a Phase I/IIA clinicaltrial of ORY-1001, a novel and highly selective LSD1 inhibitor, in patients with relapsed or refractory acute leukemia. This first-inhuman trial is currently open at the Hospital Vall d’Hebron in Barcelona, Spain and additional study sites in Spain and in the United Kingdom will be incorporated shortly.

Click here to see the full Press Release.

Share this story